Reparative resynchronization in ischemic heart failure: an emerging strategy.
Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.
Center for Regenerative Medicine and Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic , Stabile 5, 200 First Street SW, Rochester, MN 55905 , USA terzic.andre@mayo.edu.
Satsuki
S
Yamada
Andre
A
Terzic
D058406:Cardiac Resynchronization Therapy / Q000379:methods*; D006333:Heart Failure / Q000150:complications / Q000628:therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy; D017202:Myocardial Ischemia / Q000150:complications / Q000628:therapy*; D012038:Regeneration / Q000502:physiology*; D033581:Stem Cell Transplantation / Q000379:methods
biologics; cardiac resynchronization therapy; clinical trial; dyssynchrony; heart failure; myocardial infarction; regenerative medicine; stem cells